Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch

November 29, 2021 6:45 AM EST

Shares of Merck (NYSE: MRK) are down 1.7% in pre-open Monday after Citi analyst Andrew Baum downgraded to Neutral from Buy with a price target of $85.00 per share from the prior $105.00.

First, the analyst sees a high probability that Merck will terminate islatravir development in the coming months amid strong regulatory... More

UPDATE: Citi Downgrades Merck (MRK) to Neutral

November 29, 2021 4:45 AM EST

(Updated - November 29, 2021 5:25 AM EST)

Citi analyst Andrew Baum downgraded Merck (NYSE: MRK) from Buy to Neutral with a price target of $85.00 (from $105.00).

The analyst comments "We are downgrading MRK to Neutral. We place a high probability that MRK will abandon... More

Merck (MRK) PT Lowered to $82 at Morgan Stanley

November 29, 2021 1:56 AM EST

Morgan Stanley analyst Matthew Harrison lowered the price target on Merck (NYSE: MRK) to $82.00 (from $88.00) while maintaining a Equalweight rating.... More

It's Likely to Take Two Weeks to Understand 'Nu' Strain Impact, What We Know So Far - Morgan Stanley

November 26, 2021 9:11 AM EST

Morgan Stanley analyst, Matthew Harrison, in conjunction with the rest of the Biotech team, published a note containing the points of interest regarding B.1.1.529. Key points include:

The variant has 32 mutations in the spike protein (the region that vaccines create antibodies against).It is a new variant first identified n Botswana.The mutations are 'cumulative' suggesting the variant emerged in a chronically infected immunosuppressed patient.>80 samples have... More

FDA posts briefing documents on Merck (MRK) /Ridgeback antiviral molnupiravir

November 26, 2021 9:07 AM EST

FDA posts briefing documents on Merck (NYSE: MRK) /Ridgeback antiviral molnupiravir

... More

Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

November 26, 2021 6:46 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo... More

Pfizer (PFE), Other Coronavirus Vaccine/Antiviral Drug Stocks Climb on Virus Variant Fears

November 26, 2021 6:25 AM EST

Pfizer (NYSE: PFE), Other Coronavirus Vaccine/Antiviral Drug Stocks Climb on Virus Variant Fears

PFE +5%Moderna (NASDAQ: MRNA) +8.6%Novavax (NASDAQ: NVAX) +4.9%Ocugen (NASDAQ: OCGN) 10%Merck (NYSE: MRK) +1.3%
... More